top of page
  • Completed

NCT01029054: Phase 1/2: Carfilzomib and Lenalidomide With Dexamethasone Combination in NDMM

Updated: Sep 27, 2022

NCT01029054: Phase 1/2: Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

KRd

krd-myeloma

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma


This study is designed to evaluate the safety and to determine the maximum tolerated dose of carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple Myeloma patients who have not received treatment.


Sponsor

University of Michigan Rogel Cancer Center


Collaborators

Onyx Therapeutics, Inc.

Celgene

 

ClinicalTrials.gov Identifier: NCT01029054

Official Title: Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy

First Posted : December 9, 2009


Click here to see details on ClinicalTrials.gov

 

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

 

Drug: carfilzomib, lenalidomide plus dexamethasone

 

Blood; 2012

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

With median follow-up of 13 months (range, 4-25 months), 24-month progression-free survival estimate was 92%. CRd was well tolerated with exceptional response rates. This study is registered at http://www.clinicaltrials.gov

Click here for details



Haematologica;2014

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma

https://pubmed.ncbi.nlm.nih.gov/24972772/


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562550/pdf/099e162.pdf

 

Locations

United States, Michigan

United States, Missouri

United States, New Jersey

United States, New York

 


Posts Archive
bottom of page